After reporting stellar data at ASH, Terns is acquired for $6.7bn.

The Sentry trial hits on spleen volume reduction, but misses on symptoms.

Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.

Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.

Circle Pharma and Verismo feature in coveted sessions.

KITE-753 is to enter pivotal development – head-to-head against Yescarta.